Does Vyvanse cause gynaecomastia? This is a question raised by some patients taking lisdexamfetamine (marketed as Elvanse in the UK), a stimulant medication licensed for ADHD. Gynaecomastia — the benign enlargement of glandular breast tissue in males — is not listed as a recognised side effect in the UK Summary of Product Characteristics for Elvanse, and no established causal link currently exists. This article examines the available evidence, outlines the recognised side effects of lisdexamfetamine, explores other common causes of gynaecomastia, and explains when to seek medical advice.

Lisdexamfetamine (Elvanse) and Gynaecomastia: What the Evidence Shows

Gynaecomastia is not listed in the UK SmPC for lisdexamfetamine (Elvanse), and no established causal link exists; a prolactin-mediated mechanism is considered pharmacologically unlikely given that amphetamine-class stimulants generally suppress prolactin.

Lisdexamfetamine dimesylate is a central nervous system stimulant licensed in the UK under the brand name Elvanse (marketed as Vyvanse in the United States) for the treatment of attention deficit hyperactivity disorder (ADHD) in adults and children aged six and over. It works by increasing the availability of dopamine and noradrenaline in the brain, improving focus, impulse control, and executive function.

Gynaecomastia — the benign enlargement of glandular breast tissue in males — is not listed as a recognised side effect of lisdexamfetamine in the UK Summary of Product Characteristics (SmPC) for Elvanse, as approved by the Medicines and Healthcare products Regulatory Agency (MHRA). At present, there is no established or officially confirmed causal link between lisdexamfetamine and gynaecomastia.

A small number of anecdotal patient reports have raised questions about whether stimulant medications might contribute to hormonal changes. It is worth noting, however, that amphetamine-class stimulants such as lisdexamfetamine generally suppress rather than raise prolactin levels; a prolactin-mediated mechanism linking lisdexamfetamine to gynaecomastia is therefore considered unlikely on current pharmacological evidence. No robust clinical trial data or pharmacovigilance reports specific to lisdexamfetamine substantiate such an association. Any breast changes occurring during treatment are more likely to reflect coincidental or pre-existing causes (see below) than a direct effect of the medicine itself.

Recognised Side Effects of Lisdexamfetamine in the UK

The most common side effects of lisdexamfetamine include decreased appetite, insomnia, dry mouth, headache, and raised blood pressure; breast tissue changes or gynaecomastia are not among the recognised adverse effects in the UK SmPC.

The UK SmPC for Elvanse outlines a well-characterised side effect profile, most of which relate to its stimulant properties. Understanding these helps patients and clinicians distinguish expected effects from unexpected symptoms that may warrant further investigation. Frequency categories below follow standard EU/UK SmPC conventions.

Very common side effects (affecting 1 in 10 or more users) include:

• Decreased appetite and weight loss

• Insomnia and sleep disturbances

• Dry mouth

• Headache

• Increased heart rate and elevated blood pressure

Common side effects (affecting between 1 in 100 and 1 in 10 users) include:

• Anxiety, irritability, and mood changes

• Nausea and gastrointestinal discomfort

• Dizziness

• Changes in libido or sexual function

Changes in libido and sexual function are occasionally reported with stimulant medications and may reflect broader psychological or physiological effects. However, breast tissue changes or gynaecomastia are not currently listed among the recognised adverse effects in the UK SmPC for lisdexamfetamine (Elvanse).

It is also worth noting that weight loss — a very common effect of lisdexamfetamine — can alter the appearance of the chest area, sometimes making pre-existing or unrelated breast tissue more noticeable. This may lead some individuals to attribute breast changes to the medication when the underlying cause is different (see the section on pseudogynaecomastia below). Patients who notice any new or changing breast symptoms whilst taking lisdexamfetamine should document when the symptom began relative to starting or adjusting their dose, as this information will be valuable when speaking to a prescriber.

Other Causes of Gynaecomastia to Consider

Gynaecomastia has many causes, including puberty, hypogonadism, liver disease, hyperthyroidism, and drug-induced effects from medicines such as antipsychotics, spironolactone, and anabolic steroids, all of which should be excluded before attributing breast changes to lisdexamfetamine.

Gynaecomastia is a common condition in males, with physiological forms occurring at predictable life stages. A thorough clinical assessment is essential to identify the underlying cause before attributing breast changes to any specific medicine.

True gynaecomastia versus pseudogynaecomastia True gynaecomastia involves proliferation of glandular breast tissue and is felt as a firm or rubbery disc of tissue beneath the nipple. Pseudogynaecomastia refers to increased adipose (fatty) tissue in the chest without glandular enlargement, and is common in men who are overweight. Weight loss associated with lisdexamfetamine may make pre-existing adipose tissue more apparent, or conversely may reduce pseudogynaecomastia. A GP can distinguish between the two on clinical examination.

Physiological causes include:

• Puberty — transient gynaecomastia is common in adolescent males and typically resolves within one to two years

• Neonatal period — due to maternal oestrogen exposure

• Older age — declining testosterone levels can shift the oestrogen-to-androgen ratio

Pathological causes to consider include:

• Hypogonadism or testicular disorders

• Hyperthyroidism

• Liver disease (cirrhosis affects oestrogen metabolism)

• Chronic kidney disease

• Hyperprolactinaemia (e.g., due to a pituitary adenoma)

• Adrenal or testicular tumours

Drug-induced gynaecomastia is well documented. Medicines with established or strong associations include:

• Antipsychotics (via dopamine blockade and raised prolactin)

• Anabolic steroids and exogenous testosterone

• Spironolactone

• Cimetidine and other H2-receptor antagonists

• Finasteride and dutasteride (5-alpha-reductase inhibitors)

• Anti-androgens (e.g., bicalutamide, cyproterone acetate)

• Certain antiretrovirals

• Digoxin and ketoconazole

• Cannabis (evidence limited but frequently cited)

Given this broad differential, it is important not to assume that lisdexamfetamine is responsible for gynaecomastia without ruling out other contributing factors. A GP can arrange appropriate investigations — which may include liver function tests, renal function, thyroid function tests, morning testosterone, LH, FSH, prolactin, oestradiol, and beta-hCG — guided by the clinical picture and in line with NICE Clinical Knowledge Summary (CKS) guidance on gynaecomastia.

When to Speak to Your GP or Prescriber

Consult your GP promptly if you notice breast swelling, a firm subareolar lump, nipple discharge, or rapidly progressing changes; do not stop lisdexamfetamine without prescriber guidance.

Any new or unexplained physical change whilst taking a prescribed medication should be discussed with a healthcare professional. Whilst gynaecomastia is rarely a sign of serious illness, it can occasionally indicate an underlying condition that requires investigation and treatment.

Contact your GP or prescriber promptly if you notice:

• Swelling, tenderness, or enlargement of one or both breasts

• A firm or rubbery lump beneath the nipple area

• Nipple discharge of any kind

• Breast changes that are asymmetrical or rapidly progressing

• Any breast change accompanied by other new symptoms such as fatigue, unexplained weight changes, or testicular discomfort

Seek urgent assessment if there is a hard, irregular, or fixed lump, skin tethering, nipple retraction, or any other feature suspicious of malignancy. In line with NICE guideline NG12 (Suspected Cancer: Recognition and Referral), men aged 50 or over with a unilateral, firm subareolar mass — with or without nipple changes such as discharge or retraction — should be referred via the urgent suspected cancer pathway (two-week wait) to a breast clinic. Breast cancer is rare in men but does occur, and prompt assessment is important.

Persistent, unexplained, or progressive gynaecomastia, or abnormal hormone results, may warrant routine referral to an endocrinologist. If a testicular cause is suspected, testicular examination and ultrasound may be indicated.

When speaking to your GP, provide a full medication history — including any supplements, herbal remedies, or recreational substances — as well as information about when the breast changes first appeared and whether they correlate with any changes in your lisdexamfetamine dose.

Do not stop taking lisdexamfetamine without first speaking to your prescriber. Abruptly discontinuing stimulant medication can affect ADHD symptom control. A prescriber can help weigh the benefits and risks and explore whether any medication adjustment is appropriate.

MHRA Guidance and Monitoring During Treatment

The MHRA monitors lisdexamfetamine safety via the Yellow Card scheme; NICE NG87 recommends six-monthly monitoring of pulse, blood pressure, height, weight, and psychiatric symptoms during stimulant therapy.

The MHRA is the UK regulatory authority responsible for ensuring that medicines, including lisdexamfetamine (Elvanse), are safe and effective. The agency continuously monitors the safety of licensed medicines through its Yellow Card pharmacovigilance scheme, which collects reports of suspected adverse drug reactions from both healthcare professionals and patients.

If you believe you have experienced gynaecomastia or any other unexpected side effect whilst taking lisdexamfetamine, you are encouraged to report it via the Yellow Card scheme at yellowcard.mhra.gov.uk. These reports contribute to ongoing safety surveillance and help identify signals that may not have been apparent during clinical trials.

Experiencing these side effects? Our pharmacists can help you navigate them →

NICE guideline NG87 (Attention Deficit Hyperactivity Disorder: Diagnosis and Management) recommends that patients prescribed stimulant medications receive regular monitoring. In line with NG87, the following should be recorded at baseline, after each dose change, and at least every six months:

• Pulse and blood pressure

• Height and weight (growth should be monitored carefully in children and adolescents)

• Psychiatric symptoms, including mood changes and anxiety

• Overall treatment response and tolerability

Whilst routine hormonal monitoring is not recommended for all patients on lisdexamfetamine, clinicians should use clinical judgement when patients present with symptoms that may suggest endocrine involvement — such as unexplained breast changes, changes in libido, or fatigue — and arrange investigations as appropriate.

Patients and carers are encouraged to read the patient information leaflet supplied with Elvanse and to raise any concerns with their prescribing team. Open communication between patients and clinicians remains the most effective safeguard during long-term stimulant therapy.

Frequently Asked Questions